莫西沙星治疗成人支原体肺炎的临床疗效分析

目的评价莫西沙星在支原体肺炎治疗中的有效性。方法连续收集我院呼吸科确诊的86例社区获得性肺炎(支原体肺炎)患者,选择其中初始治疗采用莫西沙星治疗的28例患者(莫西沙星组)和采用头孢呋辛联合阿奇霉素治疗的22例患者(对照组),比较莫西沙星在成人支原体肺炎治疗中的临床疗效。结果莫西沙星组与对照组均无治疗失败病例,莫西沙星组72 h退热率优于对照组(75.0%vs.45.5%),平均热退时间短于对照组(3.07 d vs.5.23 d),获得临床稳定所需时间短于对照组(2.54 d vs.4.10 d,P<0.05),静脉应用抗生素疗程短于对照组(8.61 d vs.11.41 d,P<0.05)。两组总的抗生素疗程和住院天数差异无统计学意义。结论莫西沙星与对照组治疗成人支原体肺炎的临床有效率相似,但莫西沙星组退热快,72 h退热率高,获得临床稳定所需时间短,静脉应用抗生素疗程短。

Clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults

Objective To evaluate the clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults.Methods 86 cases with determined diagnosis of community acquired pneumonia(mycoplasma pneumonia)of respiratory department in our hospital were chosen,in which,28 patients treated with moxifloxacin(moxifloxacin group)and 22 patients treated with cefuroxime combined with azithromycin(control group)were included in the analysis.The clinical efficacy of the 2 groups was assessed.Results No failure case was observed in both groups.Compared with control group,the moxiflocaxin group had higher defervescence rate(75.0% vs.45.5%),shorter defervescence time(3.07 d vs.5.23 d).The time from the treatment to the clinical stability(2.54 d vs.4.10 d,P<0.05)and the intravenous antibiotic treatment course(8.61 d vs.11.41 d,P<0.05)in moxiflocaxin group were shorter than those in control group.There was no significant difference in the total course of antibiotics use and the hospitalization time between the 2 groups.Conclusion The clinical efficacy of the 2 groups was similar,and the moxifloxacin group has shorter defervescence time,higher 72 h defervescence rate,shorter clinical stability time and shorter intravenous antibiotic course.